abstract BACKGROUND AND OBJECTIVES: All measles-containing vaccines are associated with several types of adverse events, including seizure, fever, and immune thrombocytopenia purpura (ITP). Because the measles-mumps-rubellavaricella (MMRV) vaccine compared with the separate measles-mumps-rubella (MMR) and varicella (MMR + V) vaccine increases a toddler's risk for febrile seizures, we investigated whether MMRV is riskier than MMR + V and whether either vaccine elevates the risk for additional safety outcomes.
The measles-mumps-rubella (MMR) vaccine has been associated with several safety outcomes, including febrile seizures, [1] [2] [3] [4] fever, [5] [6] [7] immune thrombocytopenia purpura (ITP), [8] [9] [10] anaphylaxis, [11] [12] [13] and possibly arthritis/arthralgia. 14 After licensure of the combination measles-mumpsrubella-varicella vaccine (MMRV), the Advisory Committee on Immunization Practices recommended in 2006 that it preferred use of the MMRV over separate MMR and varicella (V) vaccines for the 2 recommended doses at 12 to 15 months and 4 to 6 years of age. 15 Beginning in 2006, the Centers for Disease Control and Prevention (CDC)-sponsored Vaccine Safety Datalink (VSD) conducted near realtime safety surveillance known as Rapid Cycle Analysis for several prespecified safety outcomes after MMRV. 16, 17 Rapid Cycle Analysis conducts routine vaccine safety surveillance by monitoring for prespecified postvaccination adverse events with the use of data accumulated weekly. In 2008, Rapid Cycle Analysis monitoring detected increased risk for seizures in 12-to 23-month-old children after MMRV, 18 although not for other safety outcomes. Follow-up studies verified that MMRV is associated with an approximately twofold increased risk of fever and febrile seizures 7 to 10 days after vaccination compared with separate MMR + V. 19, 20 The CDC subsequently recommended that either MMRV or MMR + V could be administered to 1-to 2-year-olds receiving their first doses; however, families without a strong preference for MMRV should receive MMR + V. 21 A subsequent study in 4-to 6-year-olds detected no association between MMRV or MMR + V and an increased risk of fever or febrile seizure. 22 Because it is clear that MMRV compared with MMR + V has a higher risk of febrile seizures, we hypothesized that MMRV may present a higher risk for additional safety outcomes. Examining this question also provided us the opportunity to investigate MMRV and MMR + V for possible association with these safety outcomes. The present study therefore had 2 goals: (1) to evaluate 7 main outcomes in relation to MMRV and MMR + V vaccines from 2000 to 2012, comparing MMRV versus MMR + V and after either vaccine; and (2) to replicate and refine our previously reported findings regarding the association of measles-containing vaccines with fever and seizure using previously unexamined data from 2008 to 2012.
METHODS

Study Population
This was a cohort study that included children aged 12 to 23 months who were members of 8 VSD sites from January 2000 through June 2012 and who received MMRV (Merck & Co) or separately administered, same-day MMR (Merck & Co) + V (Merck & Co) vaccines. Seven main outcomes were prespecified: anaphylaxis, ITP, ataxia, arthritis, encephalitis/meningitis/ encephalopathy, acute disseminated encephalomyelitis (ADEM), and Kawasaki disease. We chose these 7 outcomes based on being known adverse outcomes (ITP, anaphylaxis), theoretical/biologically plausible outcomes following MMR and/or varicella vaccines (ADEM, ataxia, arthritis, encephalitis/meningitis/ encephalopathy), and CDC input (Kawasaki Disease). Because many of these outcomes are rare, data since 2000 were included to compute more accurate background rates and to better adjust for confounders. For fever and seizure, we had previously reported seizure and fever 7 to 10 days after vaccination from January 2000 until October 2008 20 ; for the present study, therefore, we included only previously unreported seizure and fever data 7 to 10 days after vaccination from October 2008 through June 2012. Seizure and fever were identified as described previously 20, 22 ; most seizures captured as described are febrile seizures. 20 Outcomes were identified by using specific International Classification of Diseases, Ninth Revision, codes during focal and broad risk intervals tailored for each outcome ( Table 1 ). The risk intervals were chosen based on previous studies, 8, 20, 23, 24 CDC input, and expert opinion. Similar to previous vaccine safety studies that focused resources on statistically significant outcomes, 16, [25] [26] [27] [28] 
Statistical Analyses
This study conducted 2 prespecified analyses (Fig 1) . The primary analysis assessed whether MMRV versus MMR + V was associated with an increased outcome risk during outcome-specific risk intervals by using exact binomial tests, stratified according to age, gender, calendar week, and VSD site. To prevent confounding by VSD site, this analysis used data only during weeks in which a VSD site used both MMRV and MMR + V vaccines by requiring that concurrent follow-up time be available after both vaccines at the VSD site. Our goal was to minimize confounding by VSD site because diagnostic and coding practices, as well as decisions regarding which patient gets which vaccine, may be site-specific. However, from the outset, we suspected that this stringent concurrent follow-up time requirement might be problematic (eg, the MMRV vaccine was unavailable during 2008-2010 due to shortage), and secondary analyses were planned to partially overcome this limitation.
Secondary analyses evaluated whether MMRV or MMR + V was independently associated with an increased outcome risk by examining -9) , codes that began with these numbers were included.
FIGURE 1
Analytic approach for primary and secondary analyses through June 2012 for seizure and fever outcomes. at Harvard University on February 10, 2015 pediatrics.aappublications.org Downloaded from risk during a risk interval shortly after vaccination versus a comparison interval 57 to 180 days after vaccination ("case-centered analyses") 20, [29] [30] [31] ; MMRV vaccinees were examined separately from MMR + V vaccinees. For each vaccine-outcome pair, a simple logistic regression model was fit to a data set, including 1 record for each outcome event in either a risk or comparison interval. The dependent variable was whether the outcome occurred during the risk interval. The independent variable was based on the proportion of vaccinees in the risk interval on the calendar day of the case's outcome event, among all vaccinees in the case's age-gender stratum that were in either the risk or comparison interval on that date. The logit of this proportion was included as an offset in an intercept-only logistic regression model so that the fitted model yielded an estimate of the relative risk associated with being inside-versus-outside of the risk interval.
We next examined whether the difference between risk and comparison intervals differed between the vaccines. The intercept-only model was expanded by adding a binary variable indicating MMRV or MMR + V, which permits a test of the differencein-differences: whether the risk versus comparison interval contrast is different among MMRV vaccinees than among MMR + V vaccinees. This analysis addressed potential unmeasured differences between MMRV and MMR + V vaccinees that could confound our primary comparison.
For each type of outcome event and risk interval, 2 types of risk difference were calculated (often referred to as attributable risk): (1) the difference in outcome risk comparing post-MMRV risk interval versus post-MMR + V risk interval; and (2) the difference between observed and expected outcome incidence during the risk interval after each vaccine in which the expected incidence was derived from the comparison interval. We derived 95% confidence intervals (CIs) for the risk difference by using a score method for differences in proportions appropriate for sparse data. 32, 33 The upper bound indicates how large of an attributable risk could be ruled out with 95% confidence. Overall, rates for the 7 main outcomes during postvaccination risk intervals were low, with several outcomes having few or zero events in the risk interval after either vaccine. Estimated risk differences between MMRV and MMR + V were not statistically significant for any of the 7 main outcomes, although it was for seizure. Comparing MMRV with MMR + V, the risk difference that can be ruled out with 95% confidence ranged from 0.5 case (Kawasaki disease, days 1-28) to 35 cases (ataxia, days 1-42) per 100 000 MMRV doses (Table 2) . In the primary analysis, there was no statistically significant difference in risk between MMRV and MMR + V during either the focal or broad risk interval for the 7 main outcomes ( Table 3) . Analyses of seizures after October 2008 confirmed that MMRV, compared with MMR + V, was associated with a twofold increased risk 7 to 10 days after vaccination. Table 3 case counts differed from those in Table 2 because of the requirement for concurrent follow-up time after MMRV and MMR + V at each VSD site.
Secondary analyses comparing risk versus comparison intervals after MMRV or MMR + V revealed an increased risk of ITP and a decreased risk of ataxia after both vaccines (Table 4) . Analyses also detected an increased risk for anaphylaxis after MMRV. This result was based on only 2 cases, neither of which was confirmed as acute anaphylaxis after chart review; both diagnoses were related to a history of allergic reactions. Similar to the primary analysis, there were no significant differences in risk for the 7 main outcomes during any risk interval comparing MMRV with MMR + V ( Table 4) . Case-centered analyses demonstrated a significantly increased risk of seizure and fever 7 to 10 days after both MMRV and MMR + V and confirmed that MMRV, compared with MMR + V, was associated with a significantly higher risk for seizure and fever 7 to 10 days after vaccination (Table 4) .
DISCUSSION
Comparing MMRV with MMR + V, the present study found no statistically significant differences in risk for all 7 main outcomes and detected no new safety concerns comparing MMRV with MMR + V. We quantified the risk attributable to MMRV versus MMR + V that could be ruled out with 95% confidence and observed that at most, few cases could potentially be attributed to MMRV. These findings provide reassurance that these outcomes were unlikely after either vaccine.
The present study examined both measles-containing vaccines. No new safety concerns were found after either vaccine. We estimated how much risk we could rule out with 95% confidence for each of the 7 outcomes after either MMRV or MMR +V. These estimates indicate that even if an increased risk for these outcomes exists, the risk is low and rare after either measlescontaining vaccine. This study further confirmed (by using previously unanalyzed data) that MMRV and MMR + V are both associated with fever and seizure 7 to 10 days after vaccination, and validated our previous findings and those of others that MMRV versus MMR + V is associated with an excess risk of seizures 7 to 10 days after vaccination. 19, 20, [34] [35] [36] This study replicated previously reported safety findings, which provides additional reassurance that assessing the 7 main outcomes with this approach was reasonable.
The present study detected no difference in risk for ITP between recipients of MMRV compared with MMR + V. However, receipt of MMRV and MMR + V were individually associated with an elevated risk for ITP, highest during postvaccine days 14 to 28 but also during the 1-to 42-day risk interval. The similarly elevated risk for ITP after either vaccine is consistent with previous studies which found increased ITP risk after MMR in children. [8] [9] [10] To our knowledge, the present study represents the first report that MMRV is associated with a similar increased risk of ITP during the same postvaccination risk intervals as MMR.
A 2011 Institute of Medicine report concluded that the evidence supports a causal relationship between MMR vaccine and anaphylaxis. 14 Previous studies have suggested that anaphylaxis after MMR is rare (approximated at 1.5-1.8 events per 1 million doses). [11] [12] [13] In our study, neither of the 2 cases identified via electronic data as having anaphylaxis after MMRV was ultimately confirmed as acute anaphylaxis according to chart review. Analyses comparing MMRV with MMR + V did not identify any statistical difference; however, given the low frequency of anaphylaxis after administration of measles-containing vaccines, continued monitoring for anaphylaxis after these vaccines is warranted.
The present study found no difference in ataxia risk with MMRV versus MMR + V during either the 14-to 28-day period or the 1-to 42-day period after vaccination. Surprisingly, MMRV and MMR + V were both associated with decreased ataxia diagnoses after vaccination. Previous passive surveillance suggested a temporal relationship between MMR and increased ataxia, 37 whereas a more recent self-controlled case series analysis found no association between gait disturbances and MMR. 38 Overall, the Institute of Medicine concluded that the evidence was "insufficient or absent to assess an association between MMR vaccine and ataxia." 14 Although it is theoretically possible that both vaccines offer protection against ataxia, we instead favor the interpretation that this observation is more likely due to chance, outcome misclassification, or other unmeasured confounding. One potential explanation may be because We observed some small differences between analyses for fever risk after vaccination. The risk of fever 7 to 10 days after vaccination comparing MMRV with MMR + V slightly missed statistical significance in the primary analysis, whereas the secondary analyses used more data and reached statistical significance. In general, both analyses were broadly consistent with each other, as well as with previous clinical trials [5] [6] [7] [41] [42] [43] and observational studies, 20, 44 supporting the idea that MMRV compared with MMR + V increases risk of fever 7 to 10 days after vaccination. We therefore prespecified secondary case-centered analyses that included more cases; however, case-centered comparisons between MMRV and MMR + V indirectly calculated outcome risk differences, yielding wider confidence intervals. In this study, it was reassuring that neither primary nor secondary analyses detected an increased risk for any of the 7 main outcomes when comparing MMRV with MMR + V.
Our study had limitations. Despite using all the data in the secondary analyses, power remained low for a number of outcomes. The primary analysis had limited power for some outcomes other than fever and seizure. In addition, we did not conduct chart reviews other than for the 2 cases of anaphylaxis due to resource limitations, and some outcomes may have been misclassified.
For a relatively new vaccine, there is value in monitoring for safety and reporting results periodically even before all safety outcomes can be fully evaluated to potentially detect a large safety concern as early as possible. This monitoring provides the public with reassurance that surveillance is ongoing and that if a large safety problem exists, it would be detected. Our findings offer modest reassurance that there is no greatly elevated risk for any of the 7 main outcomes.
CONCLUSIONS
This study did not identify any new safety concerns associated with the MMRV or MMR + V vaccines. There was no statistically significant difference in risk for any of the 7 main outcomes evaluated comparing MMRV with MMR + V. Similarly, other than for previously known outcomes of seizure, fever, and ITP, there was no increased risk for new safety outcomes after either MMRV or MMR + V. This study confirmed that MMRV and MMR + V were associated with fever and seizure 7 to 10 days after vaccination, and that MMRV versus MMR + V is associated with an increased risk of seizures 7 to 10 days after vaccination. Power was limited for some outcomes, and ongoing monitoring is warranted. This study provides reassurance that most of these safety outcomes are extremely rare and unlikely after either vaccine.
